Amicus Therapeutics (LTS:0HF9) Scaled Net Operating Assets : 0.49 (As of Dec. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Amicus Therapeutics Scaled Net Operating Assets?

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Amicus Therapeutics's operating assets for the quarter that ended in Dec. 2024 was $535.1 Mil. Amicus Therapeutics's operating liabilities for the quarter that ended in Dec. 2024 was $147.3 Mil. Amicus Therapeutics's Total Assets for the quarter that ended in Sep. 2024 was $786.6 Mil. Therefore, Amicus Therapeutics's scaled net operating assets (SNOA) for the quarter that ended in Dec. 2024 was 0.49.

Amicus Therapeutics Scaled Net Operating Assets Historical Data

The historical data trend for Amicus Therapeutics's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amicus Therapeutics Scaled Net Operating Assets Chart

Amicus Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Scaled Net Operating Assets

Get a 7-Day Free Trial

0.29

0.30

0.31

0.44

0.50

Amicus Therapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Scaled Net Operating Assets	Get a 7-Day Free Trial															0.42	0.43	0.44	0.50	0.49

Competitive Comparison of Amicus Therapeutics's Scaled Net Operating Assets

For the Biotechnology subindustry, Amicus Therapeutics's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Amicus Therapeutics's Scaled Net Operating Assets Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Amicus Therapeutics's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Amicus Therapeutics's Scaled Net Operating Assets falls into.

Save Embed

;

Save Embed

;

Amicus Therapeutics Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Amicus Therapeutics's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2024 is calculated as

	Scaled Net Operating Assets (SNOA)		(A: Dec. 2024 )
=	(Operating Assets (A: Dec. 2024 )	-	Operating Liabilities (A: Dec. 2024 ))	/	Total Assets (A: Dec. 2023 )
=	(535.087	-	147.344)	/	777.88
=	0.50

where

	Operating Assets		(A: Dec. 2024 )
=	Total Assets	-	Cash, Cash Equivalents, Marketable Securities
=	785.033	-	249.946
=	535.087

	Operating Liabilities		(A: Dec. 2024 )
=	Total Liabilities	-	Long-Term Debt & Capital Lease Obligation	-	Short-Term Debt & Capital Lease Obligation
=	590.988	-	435.189	-	8.455
=	147.344

Amicus Therapeutics's Scaled Net Operating Assets (SNOA) for the quarter that ended in Dec. 2024 is calculated as

	Scaled Net Operating Assets (SNOA)		(Q: Dec. 2024 )
=	(Operating Assets (Q: Dec. 2024 )	-	Operating Liabilities (Q: Dec. 2024 ))	/	Total Assets (Q: Sep. 2024 )
=	(535.087	-	147.344)	/	786.557
=	0.49

where

	Operating Assets		(Q: Dec. 2024 )
=	Total Assets	-	Cash, Cash Equivalents, Marketable Securities
=	785.033	-	249.946
=	535.087

	Operating Liabilities		(Q: Dec. 2024 )
=	Total Liabilities	-	Long-Term Debt & Capital Lease Obligation	-	Short-Term Debt & Capital Lease Obligation
=	590.988	-	435.189	-	8.455
=	147.344

Amicus Therapeutics Scaled Net Operating Assets Related Terms

Thank you for viewing the detailed overview of Amicus Therapeutics's Scaled Net Operating Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Amicus Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Amicus Therapeutics Inc (LTS:0HF9) » Definitions » Scaled Net Operating Assets

Comparable Companies

Traded in Other Exchanges

FOLD:USA AM6:Germany

Address

47 Hulfish Street, Princeton, NJ, USA, 08542

Website

https://www.amicusrx.com

Amicus Therapeutics Inc is a patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, the company is committed to advancing and expanding a pipeline of cutting-edge medicines for rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.

Amicus Therapeutics Headlines

No Headlines